{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:33:13Z","timestamp":1740126793614,"version":"3.37.3"},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"24\/25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Diese R\u00fcckschau beschreibt die wesentlichen Vorg\u00e4nge bei der Erkennung der Thalidomid-Embryopathie vor rund 60 Jahren. Die systematische Analyse eines breiten Spektrums von angeborenen Fehlbildungen zahlreicher Organsysteme definiert dieses von 1959 bis 1962 geh\u00e4uft aufgetretene Krankheitsbild. Mehr als 5000 gesch\u00e4digte Menschen wurden in der Bundesrepublik Deutschland beobachtet, weltweit mindestens 10\u200a000. Heute leben in Deutschland noch etwa 2400 betroffene Erwachsene. Zahlreiche Sp\u00e4tfolgen mit chronischen Schmerzzust\u00e4nden f\u00fchren zu verminderter Lebensqualit\u00e4t. Im Gegensatz zu Europa und Kanada trat in den USA die Thalidomid-Embryopathie nicht geh\u00e4uft auf. Eine aufmerksame \u00c4rztin am FDA verhinderte die Zulassung. Auch in der DDR wurde Thalidomid nicht vertrieben.<\/jats:p>","DOI":"10.1055\/a-1951-0792","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T23:50:18Z","timestamp":1670284218000},"page":"1635-1638","source":"Crossref","is-referenced-by-count":1,"title":["Thalidomid-Embryopathie 60 Jahre"],"prefix":"10.1055","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2093-8042","authenticated-orcid":false,"given":"Eberhard","family":"Passarge","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Humangenetik, Universit\u00e4tsklinikum Essen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"issue":"24","key":"ref1","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1055\/s-0028-1111892","article-title":"Die Thalidomid-Embryopathie","volume":"87","author":"W Lenz","year":"1962","journal-title":"Dtsch Med Wschr"},{"issue":"19","key":"ref2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1055\/s-0028-1111856","article-title":"Thalidomid-Embryopathie: I. Vorkommen innerhalb und au\u00dferhalb Deutschlands","volume":"87","author":"H Weicker","year":"1962","journal-title":"Dtsch Med Wschr"},{"issue":"33","key":"ref3","first-page":"1597","article-title":"Thalidomid-Embryopathie. II. Ergebnisse individueller anamnestischer Erhebungen in den Einzugsgebieten der Universit\u00e4ts-Kinderkliniken Bonn, K\u00f6ln, M\u00fcnster und D\u00fcsseldorf","volume":"87","author":"H Weicker","year":"1962","journal-title":"Dtsch Med Wschr"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1007\/3-7985-1585-9","volume-title":"Die Contergankatastrophe \u2013 Eine Bilanz nach 40 Jahren","author":"M A Rauschmann","year":"2005"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s15014-014-0309-4","article-title":"Thalidomid-Embryopathie: eine vielf\u00e4ltige Katastrophe","volume":"26","author":"K M Peters","year":"2014","journal-title":"P\u00e4diatrie"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/tera.1420380303","article-title":"A short history of thalidomide embryopathy","volume":"38","author":"W Lenz","year":"1988","journal-title":"Teratology"},{"key":"ref7","first-page":"68","article-title":"Zur Frage einer exogenen Verursachung von schweren Extremit\u00e4tenmi\u00dfbildungen","volume":"104","author":"R A Pfeiffer","year":"1962","journal-title":"M\u00fcnch Med Wschr"},{"issue":"37","key":"ref8","first-page":"1863","article-title":"Hinweis auf eine derzeitige H\u00e4ufung hypo- und aplastischer Fehlbildungen der Gliedma\u00dfen (Dysmelie-Syndrom)","volume":"12","author":"H R Wiedemann","year":"1961","journal-title":"Med Welt"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","article-title":"Thalidomide and congenital abnormalities","volume":"2","author":"W G McBride","year":"1961","journal-title":"Lancet"},{"key":"ref10","first-page":"271","article-title":"Thalidomide and congenital abnormalities","volume":"1","author":"W Lenz","year":"1962","journal-title":"Lancet"},{"volume-title":"Die Haltung das Landes Nordrhein-Westfalen zu Contergan und den Folgen. Forschungsbericht der WWU M\u00fcnster f\u00fcr das Ministerium fu\u0308r Gesundheit, Emanzipation, Pflege und Alter des Landes Nordrhein-Westfalen (MGEPA NRW, 944 Seiten)","year":"2016","author":"N Lenhard-Schramm","key":"ref11"},{"issue":"02","key":"ref14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Research","volume":"105","author":"N Vargesson","year":"2015","journal-title":"Part C, Embryo Today"},{"issue":"03","key":"ref15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1024\/1012-5302\/a000670","article-title":"Behindertenspezifische Herausforderungen bei der pflegerischen Versorgung von Contergan-gesch\u00e4digten Menschen \u2013 eine Bedarfsanalyse","volume":"32","author":"C Samel","year":"2019","journal-title":"Pflege"},{"issue":"13","key":"ref16","doi-asserted-by":"publisher","first-page":"7145","DOI":"10.1002\/bdr2.2051","article-title":"Health-related quality of life after 50\u200ayears in individuals with thalidomide embryopathy: Evidence from a German cross-sectional survey","volume":"114","author":"A Niecke","year":"2022","journal-title":"Birth Defects Res"},{"issue":"19","key":"ref19","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1001\/jama.2010.1652","article-title":"Frances Kelsey honored for FDA Legacy","volume":"304","author":"B M Kuehn","year":"2010","journal-title":"JAMA"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"T Ito","year":"2010","journal-title":"Science"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"E S Fischer","year":"2014","journal-title":"Nature"},{"issue":"04","key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/embj.2020105375","article-title":"Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF","volume":"40","author":"S Yamanaka","year":"2021","journal-title":"Embo J"},{"issue":"02","key":"ref26","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/s0149-2918(03)80085-1","article-title":"Thalidomide: a review of approved and investigational uses","volume":"25","author":"S J Matthews","year":"2003","journal-title":"Clin Ther"},{"issue":"42","key":"ref27","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1055\/s-2001-17892","article-title":"Neue Indikationen f\u00fcr Thalidomid?","volume":"126","author":"G Tuinmann","year":"2001","journal-title":"Dtsch Med Wschr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41431-020-00785-7","article-title":"Origins of human genetics \u2013 A personal perspective","volume":"29","author":"E Passarge","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"ref29","first-page":"409","article-title":"Die Entwicklung der Humangenetik in Deutschland nach dem Zweiten Weltkrieg","volume":"11","author":"F Vogel","year":"1999","journal-title":"MedGen"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3238\/arztebl.2017.0168","article-title":"Mental disorders in people affected by thalidomide \u2013 a cross-sectional study of prevalence and psychosocial needs","volume":"114","author":"A Niecke","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1055\/a-1457-2846","article-title":"Chronische Schmerzen bei Menschen mit Thalidomid-Embryopathie. Eine explorative Analyse zu Pr\u00e4valenz, schmerzbezogenen Merkmalen und biopsychosozialen Faktoren","volume":"71","author":"A Niecke","year":"2021","journal-title":"Psychother Psych Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1951-0792.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T23:51:43Z","timestamp":1670284303000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1951-0792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":24,"journal-issue":{"issue":"24\/25","published-online":{"date-parts":[[2022,12,5]]},"published-print":{"date-parts":[[2022,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1951-0792","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}